National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Gastrointestinal Carcinoid Tumors Treatment (PDQ®)
Patient Version   Health Professional Version   En español   Last Modified: 05/16/2008



Purpose of This PDQ Summary






General Information






Cellular Classification






Stage Information






Localized Gastrointestinal Carcinoid Tumors






Regional Gastrointestinal Carcinoid Tumors






Metastatic Gastrointestinal Carcinoid Tumors






Recurrent Gastrointestinal Carcinoid Tumors






Get More Information From NCI






Changes to This Summary (05/16/2008)






More Information



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Cellular Classification

There is no histologic difference between carcinoids arising in various sites or between metastasizing and nonmetastasizing lesions. Carcinoid tumors are neuroendocrine tumors composed of uniform, round, or polygonal cells. Immunohistochemistry reveals the presence of neuron-specific enolase (NSE) and chromogranin. Electron microscopy shows neurosecretory granules. Morphologic features suggesting malignancy (cellular pleomorphism, hyperchromatic nuclei, necrosis, high mitotic activity) can occasionally be seen. Such cases are designated as atypical carcinoids and usually have an aggressive clinical course. Carcinoids are classified by their embryologic relationship to the foregut (the anterior part of the alimentary canal, from the mouth to the intestine or to the entrance of the bile duct), midgut (the middle part of the alimentary canal, from the stomach or entrance of the bile duct to or including the large intestine), or hindgut (the posterior part of the alimentary canal, including the rectum and sometimes the large intestine), which is correlated with clinical behavior and the secretion or nonsecretion of various neuroendocrine peptides. Proximal carcinoids may secrete histamine-like peptides causing a pink flush and bronchoconstriction. Peptide secretions of midgut carcinoids cause a cyanotic (purplish) flush, diarrhea, and hypotension. Hindgut carcinoids usually do not secrete syndrome-producing peptides.

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov